Abstracts

480 – Torque Teno Virus: A Predictive Biomarker for SARS-CoV-2 Vaccine Response in Immunosuppressed People

Background Solid organ transplant recipients (SOTRs) are highly susceptible to severe COVID-19 due to chronic immunosuppressive treatment aimed at preventing organ rejection, along with associated comorbidities. Their vaccine responses are often diminished compared to the general population. Identifying a biomarker that reflects immune status and predicts vaccination response is crucial for optimizing vaccination strategies. Torque…

462 – Heterogeneity of PD-1 Expression in PLHIV and Its Relationship With Host and Viral-Related Factors

Background Anti-PD-1 immunotherapy (API) can potentially reverse T-cell exhaustion, reinvigorate HIV-specific T-cell responses, and reduce the HIV reservoir in people living with HIV (PLHIV). API responsiveness is not direct associated with PD-1 expression on T-cells, suggesting that receptor heterogeneity might influence therapeutic outcomes. Therefore, we aimed to assess 1. whether PD-1 expression varies among T-cells…

449 – Combination of eCD4-IgG1 Delivered by AAV9 and AZD5582 in SIV-Infected, ART-Suppressed Infant RM

Background Latency reversal and immune-mediated clearance is a cure strategy based on eliminating HIV-infected CD4+ T cells during ART suppression. Here, we used AZD5582 to stimulate the non-canonical NF-κB pathway to reverse latency, as previously shown in adult rhesus macaques (RM). To target the reactivated reservoir via antibody-mediated cellular cytotoxicity, we used AAV9-delivered eCD4-Ig, a…

425 – Age Inversely Correlates With T-Cell Response to MVA.HIVconsvX Vaccination in PWH on ART

Background Durable antiretroviral therapy (ART)-free remission from HIV will likely require a robust and targeted T cell response to limit viral reactivation.  Methods We report a double-blind, randomized trial in people with HIV (PWH) suppressed on ART.  Participants, 21-60 years (median 41 years), received modified vaccinia Ankara (MVA)-vectored vaccines, MVA.tHIVconsv3 (M3), MVA.tHIVconsv4 (M4), alone or…

433 – Cytoplasmic Tail Engineering of Stabilized mRNA Env Immunogens Enhances Neutralizing Response

Background Certain Env features, such as low cell surface expression and conformational lability, have hampered mRNA vaccine development for HIV. We previously found that ablation of Env endocytosis motifs and incorporation of a truncated HIV/SIV chimeric cytoplasmic tail (SIV.CT) increased surface expression on virions and cells transduced with vaccinia-vectored immunogens. Here, we incorporated this SIV.CT…

446 – HLA-E Prevents Natural Killer Cell Inhibition of HIV-1 Replication in Peripheral Blood CD4+ T Cells

Background The HIV-1 Nef has been shown to alter MHC-1 presentation on infected T cells, and infection of cell lines suggest upregulation of non-canonical HLA-E may be advantageous for Natural Killer (NK) cell evasion. Conflicting clinical reports leave the role of NK cells in infection control unclear. True mechanistic understanding of HIV replication and control…

427 – Augmenting HIV-Specific CAR-T Cell Functionality by Treatment With Novel Cytokine-Based Scaffold

Background We previously described a bispecific CAR-T cell targeting two conserved gp120 epitopes (duoCAR-Ts) with potent anti-HIV activity, now in clinical trials. However, despite ART, many people living with HIV (PLWH) develop systemic inflammation associated with increased levels of TGF-β which may suppress the activity of infused duoCAR-Ts. We hypothesized that inhibiting TGF-β activity may…

434 – Improved Immunogenicity of a VLP-Forming mRNA Vaccine for HIV-1

Background The HIV-1 envelope (Env) is the sole target of broadly neutralizing antibodies and, therefore, the context in which it is presented to the immune system is critical for efficiently engaging responder B cells. We previously designed and tested in pre-clinical models a virus-like particle (VLP)-forming env-gag mRNA vaccine that elicited tier-2 neutralizing antibodies and…